1 Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets
2 Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of breakthrough cancer pain, and in the initiation, administration and dose titration of Abstral. This document should be referred to in conjunction with important information contained within the Abstral Product Monograph and the Abstral Prescribing Information at the back of this book. ABSTRAL PRESCRIBER AND PHARMACIST GUIDE 1. BACKGROUND CANCER PAIN Background Cancer Pain Medication 2. BREAKTHROUGH CANCER PAIN Defining Breakthrough Cancer Pain Diagnosing Breakthrough Cancer Pain Managing Breakthrough Cancer Pain 3. AN INTRODUCTION TO ABSTRAL Product Overview Selecting the Abstral Patient Route of Administration 4. TITRATING TO THE CORRECT DOSE Necessity of Titrating Dose Titration Switching Medication Referring Patients 5. IMPORTANT CONSIDERATIONS Adverse Effects 6. PROVIDING GUIDANCE FOR PATIENTS & CAREGIVERS Correct Treatment Administration & Adherence Monitoring Effectiveness Monitoring Side Effects Action in the Event of an Accidental Overdose Safe Keeping, Dispensing & Disposal
3 1. Background Cancer Pain Pain is a common experience among patients with cancer 1 One type of pain that occurs is background pain This is a persistent pain that occurs for a number of different reasons and can be controlled using specific pain medication Background Cancer Pain Medication There are a range of pharmacological and non-pharmacological treatments that can be used to help control background cancer pain. However, the most commonly prescribed forms of cancer pain medication are opioids. These should be prescribed in long-acting form and be taken regularly by patients in order to provide effective relief from background cancer pain. Options for the Treatment of Uncontrolled Background Cancer Pain Increase medication dosing Change medication Add another medication to existing one Explore non-pharmacological treatments If a patient s persistent background cancer pain is being adequately controlled, but there are still complaints of severe pain, this may indicate breakthrough cancer pain. This is explained in more detail in the next section.
4 2. Breakthrough Cancer Pain Breakthrough cancer pain is characterized by a short episode of severe pain that occurs in addition to persistent background pain in cancer patients It is a common problem in cancer patients, either as a direct or indirect result of cancer or cancer treatment 1 Engaging with patients is a vital part of supporting them in the management of their breakthrough pain, from diagnosis through to treatment and assessment Defining Breakthrough Cancer Pain While there is no universally accepted definition for breakthrough cancer pain, the European Association for Palliative Care guidelines quotes a helpful working definition of breakthrough pain taken from Breakthrough pain: definition, prevalence, and characteristics by Portenoy RK, Hagen NA (Pain 1990). Breakthrough pain is defined as: [The] transitory exacerbation of pain that occurs in addition to otherwise stable persistent pain. 2 Types and Triggers of Breakthrough Cancer Pain PREDICTABLE incident breakthrough cancer pain 1 - Voluntary triggered by movement such as walking - Involuntary triggered by reflex movement such as coughing - Procedural related to a therapeutic intervention e.g. wound dressing UNPREDICTABLE spontaneous breakthrough cancer pain 1 - unrelated to any identifiable action
5 Diagnosing Breakthrough Cancer Pain Before making a diagnosis of breakthrough cancer pain it is important first to take the following steps: (i) Assess whether a patient s complaint of pain is due to inadequately controlled background cancer pain (ii) Optimize background cancer pain medication as necessary (described in Options for the Treatment of Uncontrolled Background Cancer Pain in section 1) to help ameliorate the breakthrough cancer pain episodes 1 Diagnosing Breakthrough Cancer Pain Questions for the patient 1. Can you describe the pain? 2. Does the pain coincide with movement, e.g., walking or coughing? 3. Does the pain occur at or around the time that your regular pain medicine is due? Breakthrough cancer pain diagnostic markers 1. Severe pain in addition to controlled background pain 1 2. Yes (predictable, incident breakthrough cancer pain) No (spontaneous breakthrough cancer pain) 3. Does not coincide with regular pain medication dosing Managing Breakthrough Cancer Pain
6 3. An Introduction to Abstral Product Overview Abstral is a sublingual fentanyl tablet indicated only for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. 3 Abstral should be prescribed and administered in accordance with the approved information contained within the Abstral Product Monograph. Abstral should not be used for any indication other than that for which it is approved. Selecting the Abstral Patient In all cases, reference should be made to the relevant sections of the Abstral Product Monograph to ensure appropriate selection of patients. Abstral should only be administered to adult patients who are considered tolerant to their opioid therapy for persistent baseline cancer pain. Patients can be considered opioid tolerant if they take at least 60 mg oral morphine per day, or 25 micrograms transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, or an equianalgesic dose of another opioid for a week or longer. Abstral is contraindicated for use in opioid non-tolerant patients including those using opioids intermittently, on an as needed basis. Fentanyl products which are designed to manage breakthrough pain, including Abstral, should not be used in patients who are receiving partial opioid agonists such as buprenorphine or agents with some opioid effects such as tramadol, as the safety of their concomitant use has not been established. Abstral is contraindicated in the management of acute or postoperative pain, including headache/migraine, dental pain, or use in the emergency room. In selecting suitable patients for Abstral it is also important to assess whether they have demonstrated an addiction, or may be at risk of addiction, to their background pain medication. In turn, patients should be informed about the risk of addiction (other side effects are discussed in a later section) associated with the opioid class of treatments, including Abstral, in order to engage them fully in the selection process. It is also important to assess whether the patient might be at risk from accidental overdose or intentional suicide.
7 Route of Administration Patients selected to use Abstral for the management of their breakthrough cancer pain should be given the following important information about administering their medication: 1. Take tablet at onset of breakthrough cancer pain episode 2. Place tablet directly under the tongue at the deepest part 3. Do not swallow, chew or suck the tablet 4. Allow the tablet to dissolve 5. Do not consume anything until the tablet has completely dissolved
8 4. Titrating to the correct dose Necessity of Titrating Patients using Abstral must be individually titrated until they achieve the optimal dose. Dose titration The object of dose titration is to identify an optimal maintenance dose for ongoing treatment of breakthrough pain episodes. This optimal dose should provide adequate analgesia with an acceptable level of adverse reactions. The optimal dose of Abstral will be determined by upward titration, on an individual patient basis. Several doses are available for use during the dose titration phase. The initial dose of Abstral used must be 100 micrograms, titrating upwards as necessary through the range of available dosage strengths. Patients should be carefully monitored until an optimal dose is reached. Direct switching from other fentanyl containing products to Abstral must not occur without re-titration because of differences in pharmacokinetic profiles, different absorption profiles and individual variability. If patients are switched from another fentanyl containing product, a new dose titration with Abstral is required and must be started on no greater than 100 micrograms of Abstral. When prescribing, do not switch patients from any other fentanyl product to Abstral as Abstral is not equivalent on a mcg per mcg basis with any other fentanyl product.
9 Start all patients with a single 100 mcg tablet. If adequate analgesia is obtained within 30 minutes of administration of the 100 mcg tablet, continue to treat subsequent episodes of breakthrough pain with this dose. Patients must wait at least 2 hours before treating another episode of breakthrough pain with ABSTRAL. Subsequent Dose/Titration The following dose titration regimen is recommended, however in all cases the physician should take into account the clinical need of the individual patient, age, co-existing illness or medical condition, and concomitant medications. If adequate analgesia was not obtained with the first 100 mcg dose, continue dose escalation in a stepwise manner over consecutive breakthrough episodes until adequate analgesia with tolerable side effects is achieved. Increase the dose by 100 mcg multiples up to 400 mcg as needed. If adequate analgesia is not obtained with a 400 mcg dose, the next titration step is 600 mcg. If adequate analgesia is not obtained with a 600 mcg dose, the next titration step is 800 mcg. During titration, patients can be instructed to use multiples of 100 mcg tablets and/or 200 mcg tablets for any single dose. Instruct patients not to use more than 4 tablets at one time. Doses above 800 mcg Abstral should not be used. Once adequate pain relief is achieved with a dose between 100 and 800 mcg Abstral, the patient should get a prescription for Abstral of the dose determined by titration (i.e. 100, 200, 300, 400, 600 or 800 mcg) to treat subsequent episodes. Single doses should be separated by at least 2 hours. Abstral should only be used once per breakthrough cancer pain episode, i.e. Abstral should not be redosed within an episode. During any episode of breakthrough cancer pain, if adequate pain relief is not achieved after Abstral, the patient may use a rescue medication (other than Abstral, after 30 minutes) as directed by their healthcare provider.
10 ABSTRAL TITRATION PROCESS The initial dose is 100 mcg ABSTRAL Adequate pain relief achieved within 30 minutes? Yes Use this dose for subsequent breakthrough pain episodes No Rescue medication is permitted (other than ABSTRAL, after 30 minutes) Increase ABSTRAL dose at next breakthrough pain episode by incremental titration according to table below ABSTRAL dosing for a subsequent episode should be separated by at least 2 hours Abstral Dose 200 mcg 2 x 100 mcg tablets, or 1 x 200 mcg tablet 300 mcg 400 mcg 600 mcg 800 mcg Using 3 x 100 mcg tablets, or 1 x 300 mcg tablet 4 x 100 mcg tablets, or 2 x 200 mcg tablets, or 1 x 400 mcg tablet 3 x 200 mcg tablets, or 1 x 600 mcg tablet 4 x 200 mcg tablets, or 1 x 800 mcg tablet In order to minimise the risk of opioid related adverse reactions and to identify the appropriate dose, it is imperative that patients be supervised closely by health professionals during the titration process.
11 Maintenance therapy: Once an appropriate dose for pain management has been established, instruct patients to use only one ABSTRAL tablet of the appropriate strength per dose. Maintain patients on this dose. If adequate analgesia is not obtained after use of ABSTRAL, the patient may use rescue medication other than Abstral (after 30 minutes) as directed by their health care provider. No more than one dose of ABSTRAL may be used to treat an episode of breakthrough pain. Patients must wait at least 2 hours before treating another episode of breakthrough pain with ABSTRAL. Dose Re-Adjustment If the response (analgesia or adverse reactions) to the titrated ABSTRAL dose markedly changes, an adjustment of dose may be necessary to ensure that an optimal dose is maintained. During maintenance treatment, if the prescribed dose no longer adequately manages the breakthrough cancer pain episode for several consecutive episodes, increase the dose of Abstral as described in Dose Titration. Once a successful dose is determined, each episode is treated with a single tablet. Use of Abstral should be limited to four episodes of breakthrough pain per day, and administration of Abstral must be separated by at least 2 hours. If more than four episodes of breakthrough pain are experienced per day, then the dose of the long-acting opioid used for persistent underlying cancer pain should be re-evaluated. If the long-acting opioid or dose of long-acting opioid is changed, then the ABSTRAL dose should be re-evaluated and retitrated as necessary to ensure the patient is on an optimal dose. It is imperative that any dose re-titration of any opiate analgesic is monitored carefully by a health professional.
12 Switching Medication 1. Switching to Abstral from another opioid for breakthrough cancer pain Different treatments are not equivalent, 3 so always start titration of Abstral with a dose of 100 micrograms Refer to Abstral Product Monograph for further important information about initiating treatment with Abstral 2. Switching from Abstral to another opioid for breakthrough cancer pain First assess whether the patient has been titrated to the correct dose (and re-titrate as necessary) before considering a switch of breakthrough cancer pain medication 3. Stopping Abstral altogether For patients no longer requiring any opioid therapy, the Abstral dose should be taken into consideration before a gradual downward titration of opioids, to minimise possible withdrawal effects, such as anxiety, tremor, sweating, paleness, nausea and vomiting. In patients who continue to take their chronic opioid therapy for persistent pain, but no longer require treatment for breakthrough pain, Abstral therapy may usually be discontinued immediately. Referring Patients Patients who do not experience adequate pain relief for their breakthrough cancer pain episodes despite titration should first be reassessed so that their pain management strategy can be reviewed and modified as appropriate. If, after continued monitoring, patients continue to receive inadequate pain relief they should be referred to a pain or palliative care specialist with an interest in breakthrough cancer pain.
13 5. Important Considerations Treatment with opioid-based formulations can be associated with adverse effects. However, the risk of serious adverse effects is reduced if these medications are used under the following conditions: In the right patient (as outlined in the section entitled Selecting the Abstral Patient ) Within the parameters of the titration schedule (refer to Section 4 Titrating to the Correct Dose ) In accordance with the approved product indications and information (refer to Abstral Product Monograph) Adverse Effects The most serious adverse reactions associated with all opioids including Abstral are respiratory depression (potentially leading to apnea or respiratory arrest), circulatory depression, hypotension and shock. 3 Prescribers should therefore monitor for early evidence of respiratory depression throughout the titration and treatment process. Other very commonly reported adverse reactions include nausea, headache, constipation and somnolence/fatigue. 3 Further information on adverse reactions can be found in the Abstral Product Monograph. To avoid risk of addiction or accidental overdosing, patients who have reached their optimal dose of Abstral following titration should be limited to a maximum of four Abstral doses per day. 3
14 6. Providing Guidance for Patients and Caregivers In addition to referring patients and caregivers to the Abstral Patient Information leaflet, and ensuring they are aware of and understand the information contained within that, patients receiving Abstral or their caregivers should be given the following instructions by the physician: 1. Patients should be informed that accidental use by individuals (including children) other than the patient for whom it was originally prescribed, may lead to severe, even fatal, consequences. 2. Patients should be advised that ABSTRAL contains fentanyl, an opioid pain medicine similar to morphine, hydromorphone, methadone, oxycodone and oxymorphone. 3. Patients should be advised that ABSTRAL should be taken as directed by the physician and the dose of ABSTRAL should NEVER be adjusted without the prescribing physician s instruction. a. The dose of ABSTRAL will be adjusted until the physician finds the right dose for the patient that achieves adequate analgesia with tolerable side effects. b. ABSTRAL should be used only one time for each episode of breakthrough cancer pain. Doses of Abstral should be separated by at least 2 hours. c. ABSTRAL should not be used for more than four episodes of breakthrough cancer pain in one day. If the patient has more than four episodes of breakthrough pain each day, the dose of the opioid pain medicine for the persistent baseline cancer pain may need to be changed. d. Once the right dose for the patient has been found, the patient should not change the dose of ABSTRAL unless directed by their physician. 4. ABSTRAL comes in individually sealed child-resistant blister packages. Patients should be advised not to open the package until ready to use. Once opened, the entire ABSTRAL sublingual tablet should be used right away. Instructions for opening the blister package are included in the Consumer Information. 5. Patients should be advised not to eat or drink anything until the ABSTRAL sublingual tablet is completely dissolved under their tongue and they can no longer feel it in their mouth.
15 6. Patients should be advised to never chew, suck or swallow this medication, as this will decrease its activity. 7. Patients should be advised that ABSTRAL may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating machinery). 8. Patients should be advised that ABSTRAL should not be combined with alcohol or other CNS depressants (e.g. sleep medications, tranquilizers) because dangerous additive effects may occur, resulting in serious injury or death. 9. Patients should be advised to consult their physician or pharmacist if other medications are being or will be used with ABSTRAL. 10. Patients should be advised that ABSTRAL contains fentanyl, a drug with high potential for abuse. Patients, family members and caregivers should be advised to protect ABSTRAL from theft or misuse in the work or home environment. 11. Patients should be instructed to keep ABSTRAL in a secure place out of the reach of children due to the high risk of fatal respiratory depression. 12. When ABSTRAL is no longer needed, the unused ABSTRAL sublingual tablets should be removed from their blister units and dropped into the toilet. The toilet should be flushed after all tablets are dropped in it. Blister packages and cartons should not be dropped in the toilet. ABSTRAL rapidly and completely disintegrates on administration. If for any reason a tablet is removed from the mouth before it has completely disintegrated, it should be disposed of in accordance with the instructions provided above. 13. Patients should be informed that accidental exposure or misuse may lead to death or other serious medical problems. 14. Patients should be advised to report episodes of uncontrolled breakthrough pain and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication. 15. Patients should be advised of the most common adverse reactions that may occur while taking ABSTRAL: nausea, constipation, somnolence and headache. 16. Patients should be advised that ABSTRAL should never be given to any one other than the individual for whom it was prescribed.
16 17. Women of childbearing potential who become or are planning to become pregnant should be advised to consult a physician prior to initiating or continuing therapy with ABSTRAL. Women who are breast-feeding or pregnant should not use ABSTRAL. Monitoring Effectiveness The patient should continually monitor the effectiveness of Abstral during the titration phase in providing relief for their breakthrough cancer pain and report the following back to their healthcare professional: - Did they achieve pain relief at the prescribed dose? - How long did it take to achieve pain relief? Monitoring Side Effects The patient and caregiver should continually monitor for any adverse reactions and report these to their healthcare professional at their next visit, or immediately if serious Action in the Event of an Accidental Overdose Extreme drowsiness and shallow breathing may indicate that the patient has exceeded their agreed optimal dosage. Patients and caregivers should take the following action in the event of an overdose: - Seek emergency medical help by contacting the regional poison - control centre or by calling 911 immediately - Remove the tablet or any parts of it still remaining in the mouth - Alert their caregiver to what is happening - The caregiver should try to keep the patient conscious
17 Safe Keeping, Dispensing & Disposal Tablets must be stored in a locked storage space out of the reach of children to avoid risk of death Tablets must be kept in the original blister pack to protect them from moisture 3 Any unused tablets should be returned to the pharmacy and disposed of in accordance with national and local requirements 3 or, Unopened Abstral blisters can also be disposed by flushing them down the toilet as follows: 1. Remove the Abstral tablet from its blister package. 2. Drop the Abstral tablet into the toilet. 3. Repeat steps 1 and 2 for each Abstral blister. Flush the toilet after all unneeded blisters have been put into the toilet. Do not flush the Abstral blister packages or cartons down the toilet. Further Information/Advice For further information please contact the sponsor, Paladin Labs Inc., at
Subject: Important Drug Warning Announcement of a single shared REMS (Risk Evaluation and Mitigation Strategy) program for all Transmucosal Immediate Release Fentanyl (TIRF) products due to the potential
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under This Program Abstral (fentanyl)
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
What you should know about treating your pain with opioids Important information on the safe use of opioid pain medicine. If your healthcare provider has determined that opioid therapy is right for you,
Narcotic drugs used for pain treatment Version 4.3 Strategy to restrict the pack sizes or the type of packaging available in public pharmacies. 1. Introduction The document describing the strategy of the
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
Getting the best result from Opioid medicine in the management of chronic pain Your doctor has prescribed you opioid medicine to help you manage your chronic pain. This patient information leaflet gives
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
SELECTED OPIATES TOXICITY A MODERN DAY EPIDEMIC Learning Objectives: 1. Identify the names and reasons/circumstances for additional toxicity of SELECTED OPIATES hydromorphone DILAUDID Methadone Fentanyl/DURAGESIC
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency
POST-TEST University of Wisconsin Hospital & Clinics True/False/Don't Know - Circle the correct answer T F D 1. Changes in vital signs are reliable indicators of pain severity. T F D 2. Because of an underdeveloped
Version 2.0 with MST example Introduction The following pages explain what opioids are and what we think you may want to know about them. There is quite a lot of information here, most of it is based on
Prior Authorization Guideline Guideline: CSD - Suboxone Therapeutic Class: Central Nervous System Agents Therapeutic Sub-Class: Analgesics and Antipyretics (Opiate Partial Agonists) Client: County of San
KENTUCKY ADMINISTRATIVE REGULATIONS TITLE 201. GENERAL GOVERNMENT CABINET CHAPTER 9. BOARD OF MEDICAL LICENSURE 201 KAR 9:260. Professional standards for prescribing and dispensing controlled substances.
Initial Date of Approval: August 25, 2011 NDA 200533 NUCYNTA ER (tapentadol) tablets Opioid analgesic Janssen Pharmaceuticals, Inc. Titusville, NJ 08560 1-800-526-7736 RISK EVALUATION AND MITIGATION STRATEGY
MEDICATION GUIDE SUBOXONE (Sub-OX-own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.35 Subject: Tramadol Acetaminophen Page: 1 of 8 Last Review Date: September 18, 2015 Tramadol Acetaminophen
Strong opioids (painkillers) in palliative care what you should know Patient Information Author ID: JG Leaflet Number: PC 006 Version: 1 Name of Leaflet: Strong opioids (painkillers) in palliative care
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
WAC 246-853-660 Pain management Intent. These rules govern the use of opioids in the treatment of patients for chronic noncancer pain. WAC 246-853-661 Exclusions. The rules adopted under this section do
Considerations when Using Controlled Substances to Treat Chronic Pain By Mary-Beth F. Plum, Pharm.D. Impact of Chronic Pain Acute pain is the body s response to environmental dangers, and it helps protect
Chronic Pain Management Protocol (Pain lasting >90 days, excluding pain due to malignancy or at the end of life) Prior to initiating opioid medications for a chronic problem, at transition from acute pain
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
Prescription drug abuse has been declared an epidemic by the Centers for Disease Control. According to 2012 San Diego Medical Examiner data, the number one cause of non-natural death is due to drug overdoses
MQAC Rules for the Management of Chronic Non-Cancer Pain Effective January 2, 2012 246-919-850 Pain management Intent. These rules govern the use of opioids in the treatment of patients for chronic noncancer
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
MEDICATION GUIDE VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection.
The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office Adopted April 2013 for Consideration by State Medical Boards 2002 FSMB Model Guidelines
Medication Assisted Therapy and Pregnancy: An Introduction Deborah A. Orr, Ph.D. The Center For Drug Free Living Adapted from the NIDA Blending Initiative Curriculum Presentation Objectives Define opioids
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
FACTSHEET 6 ON PALLIATIVE CARE PRINCIPLES OF PAIN CONTROL 1: OPIOID ANALGESICS Pain remains the most feared symptom among cancer patients. Many patients with non-malignant, life-threatening disease also
Update and Review of Medication Assisted Treatments for Opiate and Alcohol Use Disorders Richard N. Whitney, MD Medical Director Addiction Services Shepherd Hill Newark, Ohio Medication Assisted Treatment
MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION Mark Fisher Program Administrator State Opioid Treatment Adminstrator Kentucky Division of Behavioral Health OBJECTIVES Learn about types of opioids and
Opioid Treatment Agreement 1. I understand that my provider and I will work together to find the most appropriate treatment for my chronic pain. I understand the goals of treatment are not to eliminate
A GUIDE FOR USERS UNaltrexone abstinence not using a particular drug; being drug-free. opioid antagonist a drug which blocks the effects of opioid drugs. dependence the drug has become central to a person
A Review of the Impacts of Opiate Use in Ontario: Summary Report A Provincial Summary Report of the Impacts of the Discontinuation of Oxycontin in Ontario: January to August 2013 December 2013 This report
Opioid s - Guide to Practice 2013 Updated as Version 2 - November 2014 2013. The EMR PCC grants permission to reproduce parts of this publication for clinical and educational use only, provided that the
Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery Marvin D. Seppala, MD Chief Medical Officer Hazelden Betty Ford Foundation This product is supported by
Opioid Addiction and Methadone: Myths and Misconceptions Nicole Nakatsu WRHA Practice Development Pharmacist Learning Objectives By the end of this presentation you should be able to: Understand how opioids
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
Controlling Pain Part 2: Types of Pain Medicines for Your Prostate Cancer The following information is based on the general experiences of many prostate cancer patients. Your experience may be different.
EMA/764409/2015 Summary of the risk management plan (RMP) for Ionsys (fentanyl) This is a summary of the risk management plan (RMP) for Ionsys, which details the measures to be taken in order to ensure
OFFICE-BASED BUPRENORPHINE THERAPY FOR OPIOID DEPENDENCE: IMPORTANT INFORMATION FOR PRESCRIBERS BUPRENORPHINE-CONTAINING TRANSMUCOSAL PRODUCTS I. INTRODUCTION The purpose of this brochure is to provide
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
Substitution Therapy for Opioid Dependence The Role of Suboxone Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015 Objectives Recognize the options available in treating opioid
Patient information Using strong Opioids to control your pain Published: April 2013. Date for review: April 2016 Introduction This leaflet explains what strong opioids (pronounced oh-pee-oyds) e are and
CONTROLLED SUBSTANCE CONTRACT The purpose of this contract is to protect my access to controlled substances and to protect our ability to prescribe for you. The long-term use of substances such as opiates
MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
Use of Buprenorphine in the Treatment of Opioid Addiction Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Executive Summary Which of the following is an
Policy on Opioid Drugs for Non-Cancer Pain and Patient Medication Agreement I understand that I have apain problem that has failed to respond to other treatments. It is recommended that I begin or continue
Principles of Highly Effective Pain Managers This pocket-size guide presents important principles of pharmacologic pain management and highly effective ways for the clinician to put these principles into
Pain and problem drug use Information for patients Prepared by the British Pain Society in consultation with the Royal College of Psychiatrists, the Royal College of General Practitioners and the Advisory
Nurses Self Paced Learning Module on Pain Management Dominican Santa Cruz Hospital Santa Cruz, California Developed by: Strategic Planning Committee Dominican Santa Cruz Hospital 1555 Soquel Drive Santa
DISPENSING OR SELLING NALOXONE Guidance for pharmacy professionals when dispensing or selling naloxone as a Schedule II drug. UPDATED ON: August 10, 2016 Purpose The intent of this document is to provide
Pain Medication What you need to know about opioid analgesics Pain Medication What you need to know about opioid analgesics Developed for the McGill University Health Centre (MUHC) by the Task Force for
Palliative Medicine, Pain Management, and Hospice Devon Neale, MD Assistant Professor Dept of Internal Medicine UNM School of Medicine Pall-i- What??? Objectives: Provide information about Palliative Medicine
Triage, Assessment & Treatment Methadone 101/Hospitalist Workshop Launette Rieb, MSc, MD, CCFP, FCFP Clinical Associate Professor, Dept. Family Practice UBC American Board of Addiction Medicine Certified
Harnessing National Data Sets to Measure Safety of Opioid Treatment: National Survey on Drug Use and Health (NSDUH) and VA Data William C. Becker, MD Assistant Professor, General Internal Medicine VA Connecticut
Opioid analgesics vary in potency, side effect and pharmacokinetic profile. Therefore the Opioid Conversion Guidelines has been developed to assist when changing opioid drug therapy. When opioid rotating
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
JENNIFER M. GRANHOLM GOVERNOR STATE OF MICHIGAN DEPARTMENT OF COMMUNITY HEALTH LANSING JANET OLSZEWSKI DIRECTOR Michigan Board of Nursing Guidelines for the Use of Controlled Substances for the Treatment
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring, MD 20993 NDA [######] LABELING SUPPLEMENT AND PMR REQUIRED [APPLICANT NAME] [ADDRESS] Attention: [CONTACT NAME] [TITLE]
The Journal of the Oklahoma State Medical Association Opioid Prescribing Guidelines for Oklahoma Health Care Providers in the Office-Based Setting Layne E. Subera, DO; Mark A. Brandenburg, MD; Avy Doran-Redus,
WITHDRAWAL OF ANALGESIA AND SEDATION Patients receiving analgesia and/or sedation for longer than 5-7 days may suffer withdrawal if these drugs are suddenly stopped. To prevent this happening drug doses
Palmer MacKie, MD MS Director, Integrative Pain Program, Eskenazi Department of Medicine, IUSOM Attorney General s Prescription Drug Abuse Task Force Member AIT Laboratories Advisory Board In 2009, 44%
MUSC Opioid Analgesic Comparison Chart Approved by the Pharmacy and Therapeutics Committee (February 2006, November 2009, March 2010, December 2011) Prepared by the MUSC Department of Pharmacy Services
A Guide to pain relief medicines For patients receiving Palliative Care 1 Which pain medicines are you taking? Contents Page No. Amitriptyline 8 Codeine 9 Co-codamol 10 Co-dydramol 11 Diclofenac (Voltarol
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Opiate Dependence Treatments, Oral Buprenorphine Agents - Pharmacy